Table 1.
Summarization of the included studies.
| Study | Country | Type | Site | Sample size | IM | Follow-up (median) | Disease-freee survival | Overall survival | NOS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | R0/Recur | R1/Recur | |||||||||
| DeMatteo et al., (6) | USA | Observ | Mix | 80 | 65/NA | 15/NA | No | 24 (1–175) mo | NA | 2.69 (0.67, 10.89)*** | 7 |
| Pierie et al., (15) | USA | Observ | Mix | 39 | 35/13 | 4/3 | No | 38 (1–159) mo | 1.44 (0.29, 7.24) | NA | 7 |
| Rutkowski et al., (12) | Poland | Observ | Mix | 328 | 253/102 | 75/46 | No | 31 (4–292) mo | 1.62 (1.12, 2.35)** | NA | 7 |
| Gouveia et al., (16) | Portugal | Observ | Mix | 96 | 78/7 | 18/5 | No | 42 (1–206) mo | 3.03 (0.96, 9.56)** | 1.54 (0.34, 7.08)*** | 7 |
| Nikfarjam et al., (17) | USA | Observ | Mix | 40 | 35/15 | 5/1 | Yes | 24 (1–74) mo | 0.81 (0.18, 3.55) | NA | 7 |
| Catena et al., (18) | Italy | Observ | Stomach | 151 | 132/NA | 19/NA | No | 101 (11–132) mo | 2.4 (1.1, 4.3)** | NA | 7 |
| Huang et al., (19) | China | Observ | Stomach | 85 | 82/24 | 3/1 | Yes | 41 (3–100) mo | 2.04 (0.24, 17.03) | NA | 7 |
| Kim et al., (20) | Korea | Observ | Stomach | 136 | 122/5 | 14/0 | No | 29 (3–106) mo | 0.3 (0.02, 5.45) | NA | 7 |
| McCarter_Placebo et al., (21)* | USA | RCT | Mix | 353 | 330/90 | 23/9 | No | 49 mo | 1.5 (0.76, 2.99)** | NA | 8 |
| McCarter_Imatinib et al., (21)* | USA | RCT | Mix | 464 | 415/114 | 49/17 | Yes | 49 mo | 1.1 (0.66, 1.83)** | NA | 8 |
| Jakob et al., (22) | Germany | Observ | Rectum | 16 | 14/NA | 2/NA | Yes | 41 (3–110) mo | 1.27 (0.03, 49.2) | NA | 7 |
| Ahlen et al., (23) | Sweden | Observ | Mix | 79 | 61/16 | 18/15 | No | 76 (10–179) mo | 2.58 (0.75, 8.87) | 3.94 (0.24, 64.1)*** | 7 |
| Hølmebakk et al., (7) | Norway | Observ | Mix | 410 | 363/53 | 47/17 | Yes | 45 (0–175) mo | 1.08 (0.6, 1.95)** | NA | 7 |
| Cavnar_Neo-IM et al., (24) | USA | Observ | Mix | 76 | 64/NA | 12/NA | Yes | 3.05 (0.01–14.3) y | NA | 0.36 (0.05, 2.8) | 7 |
| Gronchi et al., (9) | Multi-centers | RCT | Mix | 808 | 743/225 | 65/29 | Yes | 9.1(IQR, 8–10) y | 1.35 (0.91, 1.99)** | 1.05 (0.54, 2.01) | 7 |
| Pantuso et al., (25) | Italy | Observ | Mix | 74 | 54/12 | 20/2 | Yes | 53 (4–117) mo | 0.35 (0.11, 1.14) | NA | 7 |
| Şenol et al., (26) | Turkey | Observ | Mix | 60 | 51/8 | 9/3 | Yes | 47.12 ± 33.52 mo | 2.63 (0.31, 22.26) | NA | 7 |
| Shannon et al., (27) | USA | Observ | Mix | 2,084 | 2027/231 | 57/10 | Yes | NA | NA | 1.26 (0.66, 2.4) | 8 |
| Shu et al., (28) | China | Observ | Rectum | 71 | 56/NA | 15/NA | Yes | 84 mo | 4.21 (1.34, 13.21)** | NA | 7 |
| Zhu et al., (29) | China | Observ | Stomach | 371 | 85/0 | 286/1 | Yes | 34.2 ± 20.2 mo | 3.52 (0.03, 373.1) | NA | 8 |
| Cavnar_pre-IM et al., (30)* | USA | Observ | Mix | 137 | 121/NA | 16/NA | No | 4.6 (0–29) y | 1.01 (0.58, 2.07)** | NA | 7 |
| Cavnar_IM et al., (30)* | USA | Observ | Mix | 507 | 476/NA | 31/NA | Yes | 4.6 (0–29) y | 1.29 (0.63, 2.65)** | NA | 7 |
Recur, Recurrence; Observ, Observational study including retrospective or prospective study; RCT, Data from RCTs; IM, Adjuvant Imatinib therapy; y, year; mo, month; NA, not available. Mix, Studies that analyzed more than one tumor site.
*McCarter and Cavnar each in their studies analyzed two sub-datasets of GIST patients either received Imatinib or not.
**Data of survival extracted directly from the original articles.
***Disease-specific survival which were further analyzed in combination with overall survival.